Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446270 | 0.84 | PNP (0.66) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL5870543 | 0.83 | PNP (0.54) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL453203 | 0.82 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8843873 | 0.80 | PNP (0.54) | PNP | |
| SCHEMBL2940013 | 0.79 | PNP (0.63) | PNPKDM4EMEN1ALDH1A1MAPT | |
| 8-Aminoguanine SCHEMBL21761 | 0.79 | PNP (1.00) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6265336 | 0.79 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL3072982 | 0.79 | PNP (0.53) | PNPFGFR1FGFR2 | |
| SCHEMBL2435283 | 0.76 | FGFR1 (0.59) | PNPKDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL5694187 | 0.75 | FGFR1 (0.57) | PNPFGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114047262-B | Method for separating and measuring easily-hydrolyzed large polar compound | 湖北省宏源药业科技股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-114047262-A | Method for separating and measuring easily hydrolyzed large-polarity compound | 湖北省宏源药业科技股份有限公司 | 2022-02-15 | — | — | CN | claimed |
| CN-113735857-A | Acyclovir potential impurity and preparation method thereof | 湖北省宏源药业科技股份有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-108467396-A | A kind of preparation method of Ganciclovir | 安徽海康药业有限责任公司 | 2018-08-31 | — | — | CN | claimed |
| WO-2006102970-A9 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2016-05-26 | — | — | WO | claimed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2157182-A2 | Modified short interfering RNA | Qiagen GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | claimed |
| CN-101475572-A | Chemical synthesis of triacetylganciclovir | XIAOSHUN ZHANG (CN) | 2009-07-08 | — | — | CN | claimed |
| CN-101463034-A | Preparation of triacetylganciclovir | XIAOSHUN ZHANG (CN) | 2009-06-24 | — | — | CN | claimed |
| EP-0747389-B1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-09-10 | — | — | EP | claimed |
| WO-2003033498-A2 | A PROCESS FOR THE TREATMENT OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1, 3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES LIMITED (IN) | 2003-04-24 | — | — | WO | claimed |
| US-RE38090-E1 | Antitumor activity; useful for treatment and prevention of cancers | Matsuda, Akira (JP) | 2003-04-22 | — | — | US | claimed |
| EP-0763047-B1 | NOVEL METHOD OF PRODUCING NUCLEOSIDES | HOECHST AG (DE) | 2002-01-23 | — | — | EP | claimed |
| WO-1997014709-A1 | ANTISENSE OLIGOMERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-24 | — | — | WO | claimed |
| WO-1997011944-A1 | IMPROVED PROCESS FOR PRODUCING 9-(2-HYDROXYETHOXY)-METHYLGUANINE (ACYCLOVIR) | BOEHRINGER INGELHEIM KG (DE) | 1997-04-03 | — | — | WO | claimed |
| EP-0747389-A1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | claimed |
| EP-0243670-B1 | PURINE AND PYRIMIDINE COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-07-22 | — | — | EP | claimed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| EP-0243670-A1 | Purine and pyrimidine compounds and their use as anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1987-11-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | PNP 1161/4885KDM4E 2497/4885MEN1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.